Back to GetFilings.com



Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 10-Q

 


 

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended August 31, 2004

 

or

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from              to             

 

Commission file number 0-17988

 


 

Neogen Corporation

(Exact name of registrant as specified in its charter)

 


 

Michigan   38-2364843

(State or other jurisdiction of

incorporation or organization)

 

(IRS Employer

Identification Number)

 

620 Lesher Place

Lansing, Michigan 48912

(Address of principal executive offices including zip code)

 

(517) 372-9200

(Registrant’s telephone number, including area code)

 

N/A

(Former name, former address and former fiscal year, if changed since last report)

 


 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file reports), and (2) has been subject to such filing requirements for the past 90 days.    YES  x    NO  ¨

 

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12B – 2 of the Exchange Act).    YES  x    NO  ¨

 

As of October 1, 2004, there were 8,090,000 outstanding shares of Common Stock.

 



Table of Contents

NEOGEN CORPORATION AND SUBSIDIARIES

TABLE OF CONTENTS

 

     Page No.

PART I. Financial Information

    

Item 1. Interim Consolidated Financial Statements (unaudited)

    

Consolidated Balance Sheets - August 31, 2004 and May 31, 2004

   1

Consolidated Statements of Income – Three months ended August 31, 2004 and 2003

   2

Consolidated Statements of Stockholders’ Equity – Three months ended August 31, 2004

   3

Consolidated Statements of Cash Flows – Three months ended August 31, 2004 and 2003

   4

Notes to Interim Consolidated Financial Statements – August 31, 2004

   5

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

   8

Item 3. Quantitative and Qualitative Disclosures About Market Risk

   11

Item 4. Controls and Procedures

   12

PART II. Other Information

    

Item 1. Legal Proceedings

   12

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

   12

Item 3. Defaults Upon Senior Securities

   12

Item 4. Submission of Matters to a Vote of Security Holders

   12

Item 5. Other Information

   12

Item 6. Exhibits

   12

Signatures

    

CEO Certification

    

CFO Certification

    

Section 906 Certification

    


Table of Contents

PART I – FINANCIAL INFORMATION

ITEM 1. Interim Consolidated Financial Statements (Unaudited)

 

NEOGEN CORPORATION AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS (UNAUDITED)

 

     August 31,
2004


   May 31,
2004


     (In thousands, except share
and per share amounts)

ASSETS

             

CURRENT ASSETS

             

Cash

   $ 1,554    $ 1,365

Marketable securities

     31      331

Accounts receivable, less allowance of $ 563 and $ 571

     10,357      9,924

Inventories

     12,383      12,374

Deferred income taxes

     651      651

Prepaid expenses and other current assets

     1,266      1,630
    

  

TOTAL CURRENT ASSETS

     26,242      26,275

NET PROPERTY AND EQUIPMENT

     11,328      10,952

OTHER ASSETS

             

Goodwill

     18,617      18,617

Other non-amortizable intangible assets

     675      675

Other non-current assets, net of accumulated amortization of $ 935 and $ 864

     3,371      3,456
    

  

     $ 60,233    $ 59,975
    

  

LIABILITIES AND STOCKHOLDERS’ EQUITY

             

CURRENT LIABILITIES

             

Accounts payable

   $ 2,829    $ 3,063

Accrued compensation

     1,126      1,220

Federal income taxes

     193      —  

Other accruals

     1,338      1,373
    

  

TOTAL CURRENT LIABILITIES

     5,486      5,656

LONG-TERM DEBT

     2,400      3,900

OTHER LONG-TERM LIABILITIES

     2,551      2,577

STOCKHOLDERS’ EQUITY

             

Preferred stock, $1.00 par value, 100,000 shares authorized, none issued and outstanding

     —        —  

Common stock, $.16 par value, 20,000,000 shares authorized, 8,086,917 shares issued and outstanding at August 31, 2004; 8,010,222 shares issued and outstanding at May 31, 2004

     1,294      1,282

Additional paid-in capital

     26,164      25,785

Accumulated other comprehensive income

     78      99

Retained earnings

     22,260      20,676
    

  

TOTAL STOCKHOLDERS’ EQUITY

     49,796      47,842
    

  

     $ 60,233    $ 59,975
    

  

 

See notes to interim unaudited consolidated financial statements

 

1


Table of Contents

NEOGEN CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)

 

     Three Months Ended
August 31,


     2004

    2003

     (In thousands, except
per share amounts)

Net sales

   $ 15,212     $ 12,233

Cost of goods sold

     7,707       5,973
    


 

GROSS MARGIN

     7,505       6,260

OPERATING EXPENSES

              

Sales and marketing

     3,206       2,923

General and administrative

     1,151       787

Research and development

     718       676
    


 

       5,075       4,386
    


 

OPERATING INCOME

     2,430       1,874

OTHER INCOME (EXPENSE)

              

Interest income

     2       23

Interest expense

     (24 )     —  

Other

     11       85
    


 

       (11 )     108
    


 

INCOME BEFORE INCOME TAXES

     2,419       1,982

INCOME TAXES

     835       680
    


 

NET INCOME

   $ 1,584     $ 1,302
    


 

NET INCOME PER SHARE

              

Basic

   $ .20     $ .17
    


 

Diluted

   $ .19     $ .16
    


 

 

See notes to interim unaudited consolidated financial statements

 

2


Table of Contents

NEOGEN CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (UNAUDITED)

 

     Common Stock

   Additional
Paid-in
Capital


   Accumulated
Other
Comprehensive
Income


    Retained
Earnings


   Total

 
     Shares

   Amount

          
     (In thousands)  

Balance, June 1, 2004

   8,010    $ 1,282    $ 25,785    $ 99     $ 20,676    $ 47,842  

Exercise of options and warrants

   77      12      379                     391  

Comprehensive income:

                                          

Net income for the three months ended August 31, 2004

                                1,584      1,584  

Foreign currency translation adjustments

                        (21 )            (21 )
                                      


Total comprehensive income

                                       1,563  
    
  

  

  


 

  


Balance, August 31, 2004

   8,087    $ 1,294    $ 26,164    $ 78     $ 22,260    $ 49,796  
    
  

  

  


 

  


 

See notes to interim unaudited consolidated financial statements

 

3


Table of Contents

NEOGEN CORPORATION SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

 

     Three Months Ended
August 31,


 
     2004

    2003

 
     (In thousands)  

OPERATING ACTIVITIES:

                

Net income

   $ 1,584     $ 1,302  

Adjustments to reconcile net income to net cash provided by (used in) operating activities:

                

Depreciation and amortization

     434       302  

Changes in operating assets and liabilities:

                

Accounts receivable

     (433 )     327  

Inventories

     (9 )     (463 )

Prepaid expenses and other current assets

     364       (291 )

Accounts payable and accruals

     (170 )     (1,264 )
    


 


NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES

     1,770       (87 )

CASH FLOWS USED IN INVESTING ACTIVITIES:

                

Sales of marketable securities

     300       18,113  

Purchases of marketable securities

     —         (18,369 )

Purchases of property and equipment and other assets

     (772 )     (313 )
    


 


NET CASH USED IN INVESTING ACTIVITIES

     (472 )     (569 )

CASH FLOWS FROM (USED IN) FINANCING ACTIVITIES:

                

Payments on long-term debt

     (1,500 )     —    

Net proceeds from issuance of common stock

     391       135  
    


 


NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES

     (1,109 )     135  
    


 


INCREASE (DECREASE) IN CASH

     189       (521 )

CASH AT BEGINNING OF PERIOD

     1,365       1,061  
    


 


CASH AT END OF PERIOD

   $ 1,554     $ 540  
    


 


 

See notes to interim unaudited consolidated financial statements

 

4


Table of Contents

NEOGEN CORPORATION AND SUBSIDIARIES

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENT (UNAUDITED)

 

1. BASIS OF PRESENTATION

 

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (generally accepted accounting principles) for interim financial information and with the instructions to Form 10-Q and Article 10 Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring accruals) considered necessary for a fair presentation have been included. The results of operations for the three month period ended August 31, 2004 are not necessarily indicative of the results to be expected for the fiscal year ending May 31, 2005. For more complete financial information, these consolidated financial statements should be read in conjunction with the May 31, 2004 audited consolidated financial statements and the notes thereto included in the Company’s annual report on Form 10-K for the year ended May 31, 2004.

 

2. INVENTORIES

 

Inventories are stated at the lower of cost, determined on the first-in, first-out method, or market. The components of inventories follow:

 

     August 31,
2004


   May 31,
2004


     (In thousands)

Raw materials

   $ 6,135    $ 5,487

Work-in-process

     562      526

Finished goods

     5,686      6,361
    

  

     $ 12,383    $ 12,374
    

  

 

3. NET INCOME PER SHARE

 

The calculation of net income per share follows:

 

     Three Months Ended
August 31,


     2004

   2003

     (In thousands except
per share amounts)

Numerator for basic and diluted net income per share:

             

net income

   $ 1,584    $ 1,302
    

  

Denominator:

             

Denominator for basic net income per share - weighted average shares

     8,023      7,778

Effect of dilutive stock options and warrants

     445      433
    

  

Denominator for diluted net income per share

     8,468      8,211
    

  

Net income per share:

             

Basic

   $ .20    $ .17
    

  

Diluted

   $ .19    $ .16
    

  

 

On January 2, 2004, the Company paid a 5 for 4 stock split in the form of a stock dividend. All share and net income per share amounts have been retroactively restated to reflect the split as if it took place at the beginning of the periods presented.

 

5


Table of Contents

4. STOCK REPURCHASE

 

The Company’s Board of Directors has authorized the purchase of up to 1,250,000 shares of the Company’s Common Stock. As of August 31, 2004, the Company has purchased 871,000 shares in negotiated and open market transactions. Shares purchased under this buy-back program were retired. There were no shares repurchased in the three months ended August 31, 2004 or 2003.

 

5. SEGMENT INFORMATION

 

The Company has two reportable segments: Food Safety and Animal Safety. The Food Safety segment produces and markets diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, drug residues, foodborne bacteria, food allergens, pesticide residues, disease infections and levels of general sanitation. The Animal Safety segment is primarily engaged in the production and marketing of products dedicated to animal health, including veterinary instruments and a complete line of consumable products marketed to veterinarians and animal health product distributors. Additionally the Animal Safety segment produces and markets a line of rodenticides to assist in the control of rats and mice in and around agricultural, food production and other facilities.

 

These segments are managed separately because they represent strategic business units that offer different products and require different marketing strategies. The Company evaluates performance based on total sales and operating income of the respective segments.

 

Segment information for the three months ended August 31, 2004 and 2003 follow:

 

     Food
Safety


   Animal
Safety


  

Corporate

and
Eliminations(1)


    Total

     (In thousands)

Fiscal 2005

                            

Net sales to external customers

   $ 7,200    $ 8,012    $ —       $ 15,212

Operating income

     1,316      1,197      (83 )     2,430

Total Assets

     24,787      34,764      682       60,233

Fiscal 2004

                            

Net sales to external customers

   $ 6,899    $ 5,334    $ —       $ 12,233

Operating income

     1,134      604      136       1,874

Total Assets

     21,574      18,550      8,092       48,216

(1) Includes corporate assets, consisting principally of marketable securities, and overhead expenses not allocated to specific business segments. Also includes the elimination of intersegment transactions and minority interests.

 

6. STOCK OPTIONS

 

The Company follows Accounting Principles Board (APB) Opinion No. 25, Accounting for Stock Issued to Employees, in accounting for its stock option plan. Under Opinion No. 25, no compensation expense is recognized because the exercise price of the Company’s stock options equals the market price of underlying stock on the date of grant. Had compensation expense for the Company’s stock-based compensation plans been determined based on the fair value at the grant dates for awards under those plans consistent with Statement of Financial Accounting Standards (SFAS) No. 123, Accounting for Stock-Based Compensation, the Company’s net income and net income per share would have been as follows:

 

6


Table of Contents

6. STOCK OPTIONS (CONTINUED)

 

     Three Months Ended
August 31,


 
     2004

    2003

 
     (In thousands except
per share amounts)
 

Net income:

                

As reported

   $ 1,584     $ 1,302  

Deduct-compensation expense based on fair value method

     (186 )     (180 )
    


 


Pro forma

   $ 1,398     $ 1,122  

Basic net income per share:

                

As reported

   $ .20     $ .17  

Pro forma

   $ .17     $ .14  

Diluted net income per share:

                

As reported

   $ .19     $ .16  

Pro forma

   $ .17     $ .14  

 

7. LEGAL PROCEEDINGS

 

The Company is subject to certain legal proceedings in the normal course of business that, in the opinion of management, will not have a material effect on its future results of operations or financial position.

 

8. BUSINESS ACQUISITIONS

 

On November 21, 2003, Neogen Corporation purchased 100% of the common stock of Hacco, Inc. and of Hess & Clark, Inc. from United Agri Products, Inc. a then wholly owned subsidiary of ConAgra, Inc. Hacco has principal offices in Randolph, Wisconsin, and is a producer of rodenticide products. The Hess & Clark acquisition was principally a product line purchase in which the Company acquired lines of disinfectants and antibacterials.

 

Consideration for the November 21, 2003 acquisitions was $10,000,000 in cash, including related acquisition costs. Allocation of the purchase price included current assets of $1,800,000; property, plant and equipment of $2,600,000; intangible assets of $7,400,000 (including customer intangibles of $1,900,000; patents and trademarks of $200,000 and goodwill of $5,300,000); and liabilities of $1,800,000, including an environmental remediation liability of $1,200,000. The customer based asset is expected to be amortized over 20 years. The companies are believed to be strong synergistic fits into Neogen’s overall strategy of providing food and animal safety solutions.

 

Unaudited pro forma financial information, as if the acquisitions of Hacco and Hess & Clark had taken place on June 1, 2003 is as follows:

 

     Three months ended
August 31, 2003


     (In thousands except
per share amount)

Revenue

   $ 14,769

Net income

   $ 1,517

Diluted net income per share

   $ .19

 

9. LONG TERM DEBT

 

The Company has a financing agreement with a bank providing for an unsecured revolving line of credit of $15,000,000. Interest is at prime less 1.25% or Eurodollar prime equivalent, plus 150 basis points at the Company’s option (rate elected was 3.0% at August 31, 2004). Financial covenants include maintaining current ratios and debt to earnings ratios (as defined) and specified levels of tangible net worth, all of which are complied with at the balance sheet date. The agreement matures September 1, 2006.

 

7


Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The information in this Management’s Discussion and Analysis of Financial Condition and Results of Operations contains both historical financial information and forward-looking statements. Neogen does not provide forecasts of future performance. While management is optimistic about the Company’s long-term prospects, historical financial information may not be indicative of future financial performance.

 

Safe Harbor and Forward-Looking Statements

 

Forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, are made throughout this Quarterly Report on Form 10-Q. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “seeks,” “estimates,” and similar expressions are intended to identify forward-looking statements. There are a number of important factors, including competition, recruitment and dependence on key employees, impact of weather on agriculture and food production, identification and integration of acquisitions, research and development risks, patent and trade secret protection, government regulation and other risks detailed from time to time in the Company’s reports on file at the Securities and Exchange Commission, that could cause Neogen Corporation’s results to differ materially from those indicated by such forward-looking statements, including those detailed in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

 

In addition, any forward-looking statements represent management’s views only as of the day this Quarterly Report on Form 10-Q was first filed with the Securities and Exchange Commission and should not be relied upon as representing management’s views as of any subsequent date. While management may elect to update forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, even if its views change.

 

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

 

The discussion and analysis of the Company’s financial condition and results of operations are based on the consolidated financial statements that have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires that management make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, management evaluates the estimates, including those related to receivable allowances, inventories and intangible assets. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

 

The following critical accounting policies reflect management’s more significant judgments and estimates used in the preparation of the consolidated financial statements.

 

Revenue Recognition

 

Revenue from sales of products is recognized at the time title of goods passes to the buyer and the buyer assumes the risks and rewards of ownership. This is generally at the time of shipment. Where right of return exists, allowances are made at the time of sale to reflect expected returns based on historical experience.

 

Accounts Receivable Allowance

 

Management attempts to minimize credit risk by reviewing customers’ credit history before extending credit and by monitoring credit exposure on a regular basis. An allowance for possible losses on accounts receivable is established based upon factors surrounding the credit risk of specific customers, historical trends and other information, such as changes in overall changes in customer credit and general credit conditions. Actual collections can differ from historical experience, and if economic or business conditions deteriorate significantly, adjustments to these reserves could be required.

 

8


Table of Contents

Inventory

 

Obsolete inventory is written off as it is identified against the reserve. Product obsolescence may be caused by shelf-life expiration, discontinuance of a product line, replacement products in the marketplace or other competitive situations. A reserve for obsolescence is established based on an analysis of the inventory taking into account the current condition of the asset as well as other known facts and future plans. The amount of reserve required to record inventory at lower of cost or market may be adjusted as conditions change.

 

Valuation of Intangible Assets and Goodwill

 

Management assesses goodwill and other non-amortizable intangible assets for possible impairment on no less often than an annual basis. This test was performed in the fourth quarter of fiscal 2004 and it was determined that no impairment exists. There was also no impairment indicated for 2003. In the event of changes in circumstances that indicate the carrying value of these assets may not be recoverable, management will make an assessment at any time. Factors that could cause an impairment review to take place would include:

 

  Significant underperformance relative to expected historical or projected future operating results.

 

  Significant changes in the use of acquired assets or strategy of the Company.

 

  Significant negative industry or economic trends.

 

When management determines that the carrying value of intangible assets may not be recoverable based on the existence of one or more of the above indicators of impairment, the carrying value is compared to a value determined based on projected discounted cash flows using a discount rate commensurate with the risk inherent in the Company’s current business model. Any impairment identified in this computation is given current recognition in any unissued financial statements. Changes to the discount rate used in the analysis or discounted cash flows can have a significant impact on the results of the impairment test.

 

RESULTS OF OPERATIONS

 

Executive Overview

 

On an overall basis, the Company had a 24% increase in revenues in the August 2004 quarter primarily as a result of revenue increases in the Animal Safety segment. The Animal Safety segment’s revenue increase of over 50% came principally from the Company’s November 2003 acquisition of Hacco, Inc. and Hess & Clark, Inc. Other products increased 5% compared to the August 2003 quarter. Food Safety revenues increased 4% primarily from increases in sales of dehydrated culture media. Favorable weather conditions in the current year resulted in an overall clean harvest. As a result, testing for naturally occurring toxins declined slightly compared to the prior year.

 

Gross margins were primarily affected by product mix. Operating and net income increased in the quarter as compared to the prior year from the combined effects of the additional sales and from management’s continued control of costs.

 

See the discussions below for more detailed analysis of the results for the Company’s operations for the three month period ended August 31, 2004 as compared to the same three month period of the prior year.

 

9


Table of Contents

Three Months Ended August 31, 2004 Compared to Three Months Ended August 31, 2003

 

     Three Months Ended
August 31,


  

Increase

(Decrease)


 
     2004

   2003

  
     (Dollars in Thousands)             

Food Safety

                            

Natural Toxins & Allergens

   $ 2,883    $ 2,968    $ (85 )   (2.9 )%

Bacteria & General Sanitation

     2,591      2,574      17     0.7 %

Dehydrated Culture Media & Other

     1,726      1,357      369     27.2 %
    

  

  


     
       7,200      6,899      301     4.4. %

Animal Safety

                            

Life Sciences Drug Detections & Vaccines

     1,640      1,277      363     28.4 %

Rodenticides & Disinfectants

     2,422      —        2,422     —    

Veterinary Instruments & Other

     3,950      4,057      (107 )   (2.6 )%
    

  

  


     
       8,012      5,334      2,678     50.2 %
    

  

  


     

Total Sales

   $ 15,212    $ 12,233    $ 2,979     24.4 %
    

  

  


     

 

Total revenues increased 24% in the August 2004 quarter compared to the August 2003 quarter. Revenues from sales of products related to food safety were up 4% and revenues from animal safety products were up 50%. Exclusive of the sales of products from the businesses purchased in November of 2003, total sales increased 5%.

 

The increases in sales in the Food Safety segment were primarily related to a 40% increase in sales of dehydrated culture media products. These increases came from increased market penetration of both the domestic and international markets. Increases in sales of bacteria diagnostic products were offset by a 15% decrease in sales of general sanitation products as the Company continued its efforts to shift the sales of these products from a former distributor relationship to internally produced products. The goal of this change to internally produced general sanitation products is to increase gross margins from these sales.

 

The increases in sales of the Animal Safety segment were primarily related to the sales of the products of Hacco, Inc. and Hess & Clark, Inc. that were purchased in November 2003. Without these acquisitions, other sales increased 5%. Life sciences, drug detection and vaccine products increased 28% principally from strong shipments of vaccine products during the 2004 quarter. Other sales in 2004 were primarily affected by increases in sales of an antiseptic product and a product with periodic supply difficulties offset by decreases in sales of certain products marketed for wound care. Sales of rodenticide products increased 18% in comparison to sales made in the comparable 2003 quarter under former management.

 

Gross margins in the August 2004 quarter decreased to 49% from 51% in the prior year. Food Safety margins decreased to 57% from 59% in 2004 and Animal Safety gross margins increased to 42% from 41% in the prior year. The overall decrease in gross margin was a result of product mix and the costs of new manufacturing facilities that came on line in first quarter of fiscal 2004 in Lansing and in fourth quarter of fiscal 2004 in Lexington. These new facilities will provide significantly expanded production capability and are expected to provide greater efficiencies in future periods.

 

Sales and marketing expenses increased by $283,000 in the August 2004 quarter. As a percentage of sales these expenses decreased to 21% of revenues from 24% in the August 2003 quarter. Food Safety sales and marketing expense decreased to 24% from 27% while Animal Safety sales and marketing expense decreased to 19% from 20%. In both divisions strong cost control measures were responsible for the decreases as a percentage of sales. Additionally Animal Safety was positively affected by the relationship between added Hacco sales and added sales marketing expense to service those sales.

 

General and administrative expenses increased $364,000 from 6% of sales in fiscal 2004 to 8% in the current year. The increased expenses arose primarily from the addition of Hacco as well as expenses related to the increased levels of operations of the Company. In the August 2003 quarter, administrative expenses were credited for reimbursements made by third parties to the Company for legal

 

10


Table of Contents

costs that were previously expensed related to two disputes that were settled during the quarter. Without those legal expense recoveries, general and administrative expense in the August 2003 quarter would have been 9%. In general, the Company’s general and administrative expenses are fixed in relationship to revenues.

 

Research and development expenses in the August 2004 quarter increased $42,000 but declined from 6% of sales in 2004 to 5% in the current year. Although on a quarter to quarter basis, some fluctuations of research and development expense will occur, management expects research and development expense to approximate 5% to 6% of revenues over time. These expenditures approximate 8% to 10% of revenues from products and product lines that are supported by research and development.

 

Other income decreased significantly in the August 2003 quarter as compared to the prior year. This resulted principally from decreased royalties from related limited partnerships that expired in October 2004. Federal and state income tax rates used in the computation of income tax expense in the periods remained comparable to those in the prior year.

 

Financial Condition and Liquidity

 

At August 31, 2004, the Company had $1,585,000 in cash and marketable securities, working capital of $20,756,000 and stockholders’ equity of $49,796,000. In addition, available bank lines totaled $12,500,000. Cash and marketable securities were substantially unchanged from the balance at May 31, 2004. The Company’s cash balance is a factor of drawings on the Company’s credit line.

 

Accounts receivable were $433,000 higher than at May 31, 2004. Days outstanding in account receivables decreased from 58 days at May 31, 2004 to 57 days as of August 31, 2004. Management believes that the recorded allowance is adequate to provide for accounts that may become uncollectable. Inventories at August 31, 2004 were at substantially the same level as at May 31, 2004. The decrease of $170,000 in current liabilities results from the timing of payments.

 

During the August 31, 2004 quarter, the Company continued to convert a facility in Lansing, Michigan to serve as its principal dehydrated culture media manufacturing operation. The expenditures of approximately $700,000 were financed by cash flows. Additionally, during the quarter operating cash flows were sufficient to provide for repayment of $1.5 million of the Company’s long-term credit facility.

 

Inflation and changing prices are not expected to have a material effect on operations.

 

Management believes that the Company’s existing cash as of August 31, 2004, along with its available bank revolving line of credit and cash expected to be generated from future operations, will be sufficient to fund activities for the foreseeable future. However, existing cash and bank lines may not be sufficient to meet the Company’s cash requirements to commercialize products currently under development or its plans to acquire other organizations, technologies or products that fit within the Company’s mission statement. Accordingly, the Company may be required to issue equity securities or enter into other financing arrangements for a portion of the Company’s future capital needs.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

The Company has minimal interest rate and foreign exchange rate risk exposure and no fixed rate investments or borrowings. The Company’s primary interest rate risk is due to potential fluctuations of interest rates for variable rate borrowings.

 

Generally, sales are denominated in U.S. dollars; however, because Neogen markets and sells its products throughout the world, it could be significantly affected by weak economic conditions in foreign markets that could reduce demand for its products.

 

Neogen has assets, liabilities and operations outside of the United States that are located primarily in Ayr, Scotland where the function currency is the British Pound. The Company’s investment in its foreign subsidiary is considered long-term, accordingly, it does not hedge the net investment or engage in other foreign currency hedging activities due to the insignificance of these balances to the Company as a whole.

 

11


Table of Contents

ITEM 4. CONTROLS AND PROCEDURES

 

The Company’s management, with the participation of the Company’s Chief Executive and Chief Financial Officers, has evaluated the effectiveness of the Company’s disclosure controls and procedures as of August 31, 2004. Based on that evaluation, the Company’s Chief Executive and Chief Financial Officers concluded that the Company’s disclosure controls and procedures were effective as of August 31, 2004. There were no material changes to the Company’s internal control over financial reporting in the quarter ended August 31, 2004.

 

PART II. OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

The Company is subject to certain legal proceedings in the normal course of business that, in the opinion of Management, will not have effect on its future results of operations or financial position.

 

Items 2,3,4 and 5 are not applicable and have been omitted.

 

ITEM 6. EXHIBITS

 

(a) Exhibit Index

 

31.1   – Certification of Chief Executive Officer pursuant to Rule 13a – 14 (a).
31.2   – Certification of Chief Financial Officer pursuant to Rule 13 a – 14 (a).
32.   – Certification pursuant to 18 U.S.C. section 1350

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

   

NEOGEN CORPORATION

    (Registrant)

Dated: October 11, 2004

       
   

By:

 

/S/ JAMES L. HERBERT


       

James L. Herbert

       

President and Chief Executive Officer

Dated: October 11, 2004

       
   

By:

 

/S/ RICHARD R. CURRENT


       

Richard R. Current

       

Vice President and Chief Financial Officer

 

12